Two of the most prolific patents of the modern era belong to an entrepreneurial firm, Cetus, that did not survive due to delays in the FDA approval of a drug and the resulting funding crisis. These two patents involve process innovations that defined the polymerase chain reaction (PCR), which allows DNA to be cloned. Kary Mullis, the inventor on these two patents (#4,683,202 and #4,683,195), received the 1993 Nobel Prize in Chemistry for this scientific breakthrough.
MyPatentAssets Dashboard for Patent #4,683,195:
Looking at the MyPatentAssets dashboard, we can see that patent #4,683,195 has a Patent Rank of 99.
MyPatentAssets Dashboard for Patent #4,683,202:
Looking at the MyPatentAssets dashboard, we can see that patent #4,683,202 has a Patent Rank of 99.
About Patents #4,683,195 and #4,683,202:
The present invention is directed to a process for amplifying and detecting any target nucleic acid sequence contained in a nucleic acid or mixture thereof. The process comprises treating separate complementary strands of the nucleic acid with a molar excess of two oligonucleotide primers, extending the primers to form complementary primer extension products which act as templates for synthesizing the desired nucleic acid sequence, and detecting the sequence so amplified. The steps of the reaction may be carried out stepwise or simultaneously and can be repeated as often as desired.
In addition, a specific nucleic acid sequence may be cloned into a vector by using primers to amplify the sequence, which contain restriction sites on their non-complementary ends, and a nucleic acid fragment may be prepared from an existing shorter fragment using the amplification process.
In Layman’s Terms:
In the most basic sense, Kary Mullis invented a process in which to detect, enlarge, and clone a nucleic acid sequence of DNA. A nucleic acid sequence is a succession of letters that indicate the order of nucleotides within a DNA or RNA molecule. Essentially, these patents revolutionized modern chemistry and the way we observe and work with DNA.
Based on the MyPatentAssets analysis and our own personal research and evaluation, we conclude that patents #4,683,195 and #4,683,202 hold unprecedented value.